Catalyst Dossier · compiled by CeliA 🧫

Axogen, Inc. (AXGN) (AXGN)

Electromedical & Electrotherapeutic Apparatus · market cap $2.4B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Axogen (AXGN) is a commercial-stage surgical biologics company focused exclusively on peripheral nerve repair, marketing processed nerve allografts (AVANCE), nerve connectors, and soft tissue membranes. The company is revenue-generating with $225M in 2025 sales but remains unprofitable, carrying a net loss of $16M. Its lead investigational asset — a processed nerve allograft — is in Phase 3 for peripheral nerve discontinuities, which could expand the labeled indication and addressable surgical population.

The catalyst path

2026-08-04Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Processed Nerve Allograft (human)	Phase 3	Peripheral Nerve Discontinuities

Price & technical context

3-month

+32.9%

6-month

+31.6%

12-month

+305.7%

52-wk range

$10.93–$46.19

vs 50-day MA

+4.9%

vs 200-day MA

+39.6%

Realized vol

52.8%

Max drawdown

-53.8%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AXGN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.